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The aim of this study was to describe the effect of sys-
temic alphacalcidol (1αOH vitamin D3) treatment on 
clinical and immunological parameters in patients with 
psoriatic arthropathy. Among the 19 patients investiga-
ted, 10 were treated with 0.25 µg oral alphacalcidol twice 
daily for 6 months, while 9 other patients served as con-
trols. In the peripheral blood of the treated group but not 
in the controls, a statistically significant decrease was ob-
served in the percentage of CD3/CD69-positive activated 
and CD8-positive interferon-γ-producing T cells and in 
the serum level of interferon-γ during the first 3 months 
and also in the clinical activity of the disease during the 
whole 6-month follow-up period. Our results show that 
systemic alphacalcidol treatment has an immunomodu-
latory effect on patients with psoriatic arthropathy. This 
effect is manifested by a short-term temporary decrease 
in type 1 immune responses and a continuous decrease in 
disease activity. Key words: alphacalcidol treatment; pso-
riatic arthropathy; immunomodulatory effect.
(Accepted June 30, 2008.)
Acta Derm Venereol 2009; 89: 140–144.
János Gaál, Department of Rheumatology, Kenézy 
Gyula Hospital, 2–26 Bartók Béla str., HU-4043 Debrecen, 
Hungary. E-mail: gaalja@feemail.hu
Beyond the calcaemic effect of vitamin D3 this vitamin 
also has important immunomodulatory effects. It exerts 
various effects on the monocyte-macrophage system, on 
T and B lymphocytes and on dendritic and natural killer 
(NK) cells. Regarding the monocyte-macrophage system 
it increases the phagocytotic activity of monocytes, the 
antibody-dependent cellular cytotoxicity (ADCC) re-
action and the differentiation of myeloid progenitor cells 
towards macrophage development (2–4). In addition, lack 
of vitamin D3 results in an increased risk of infections and 
an inverse relationship between the concentrations of the 
activated form of vitamin D3 calcitriol (1,25(OH)2D3) and 
mortality has been observed in human immunodeficiency 
virus (HIV)-infected adults (5, 6). 
Vitamin D3 decreases: (i) the proliferation of all T-
helper (Th) cells; (ii) the development and function of 
Th1 cells; (iii) the production of interferon-γ (IFN-γ), 
interleukin (IL)-1, IL-2, IL-5, IL-6, IL-12, tumour ne-
crosis factor (TNF) α and β; (iv) the immunoglobulin 
secretion of the B lymphocytes; and (v) the integrin-
mediated T-lymphocyte homing (1, 7–11). 
Concerning the dendritic cells (DC), vitamin D3 and 
its active metabolites inhibit their differentiation and 
maturation leading to a down-regulated expression of 
MHC-II, co-stimulatory molecules and IL-12 produc-
tion, and also a decrease in a dose-dependent manner 
in the proliferation and antigen-presenting function of 
the skin Langerhans’ cells (12, 13). Moreover, calcitriol 
enhances IL-10 production and promotes DC apoptosis 
(3). Together, these effects of activated vitamin D3 in-
hibit DC-dependent T-cell activation (12). 
There is much evidence that topical vitamin D3 com-
pounds are beneficial in dermatology. Among these are 
the local immunomodulatory effects of tacalcitol, calci-
potriol and maxacalcitol, which suppress keratinocyte 
proliferation and induce terminal differentiation and can 
be used successfully in the treatment of dermatological 
diseases, including psoriasis (14–16). In addition, in 
patients with psoriasis the systemically used calcitriol 
exerted a favourable effect on skin symptoms (17). On 
the other hand, reviewing the literature, only one study 
was found on the clinical effects of systemic vitamin D3 
analogues calcitriol and alphacalcidol (1αOH vitamin 
D3) in patients with psoriatic arthritis (PA), and no study 
has dealt with their immunomodulatory effects in these 
patients (18).
The aim of the present study was to evaluate changes 
in the function of the immune system during systemic 
alphacalcidol treatment in patients with PA using vari-
ous laboratory examinations, and to describe its effect 
on clinical parameters in these patients.
METHODS
Study population
The study population consisted of patients with rheumatoid 
arthritis (RA)-like PA, who received regular follow-up care at 
the Department of Rheumatology, Kenézy Gyula Hospital, and 
at the Department of Dermatology, University Medical School 
of Debrecen. The study was approved by the local ethics com-
mittee and informed consent was obtained from all subjects 
before the study was started.
Immunological and Clinical Effects of Alphacalcidol in Patients with 
Psoriatic Arthropathy: Results of an Open, Follow-up Pilot Study
János GAáL1, Gabriella LAKOS2, Péter SzODORAy2, Judit KISS1, Irén HORVáTH1, Edit HORKAy3, Georgina NAGy4 and  
Andrea SzEGEDI4
1Department of Rheumatology, Kenézy Gyula Hospital, 23rd Department of Internal Medicine, Departments of 3Radiology and 4Dermatology, University 
Medical School of Debrecen, Debrecen, Hungary
141Alphacalcidol in patients with psoriatic arthropathy
The diagnosis of PA was established according to the original 
diagnostic criteria of Moll & Wright (19). The diagnosis was 
made in the presence of an inflammatory arthritis (peripheral 
arthritis and/or sacroiliitis or spondylitis) and psoriasis and 
in the absence of serological tests for rheumatoid factor and 
anti-CCP (cyclic citrullinated peptide) antibodies. Overall, 19 
patients were included in the study, 10 of whom were enrolled 
into the alphacalcidol-treated group, with the remaining 9 in the 
control group. There were 6 women and 4 men in the treatment 
group with a mean age of 60 ± 8 years; the disease course of 
psoriasis was 15 ± 11 years, while the presence of arthritis was 
8 ± 6 years. The control group comprised 4 women and 5 men 
with a mean age of 53 ± 13 years; the presence of psoriasis was 
21 ± 8 years, while arthritis has been apparent for 8 ± 1 years.
Study protocol
The follow-up period was 6 months. The inclusion criteria 
were the established diagnosis of PA with polyarticular (RA-
like) joint involvement. Patients with nephrolithiasis and other 
inflammatory arthropathies were excluded. There were three 
visits during the course of the follow-up: the first visit at the 
start of follow-up, and additional visits 3 and 6 months later. 
The study window period was ± 14 days during each visit. At 
the time of each visit several clinical parameters were analysed: 
the psoriasis area and severity index (PASI), patients' global 
assessment using a 100-mm visual analogue scale (VAS), the 
activity of articular involvement by the three variable disease 
activity score (DAS28), and other routine laboratory data, such 
as erythrocyte sedimentation rate, serum calcium, phosphorous, 
urea, creatinine and liver enzymes, urine calcium/creatinine 
ratio, and immunological parameters, including the percentages 
of CD3, CD4, CD8-positive T cells, CD56-positive NK cells 
and CD19-positive B cells (20). T-cell activation was evaluated 
by HLA DR and CD69 cell surface expression and the ratios 
of Th1/Th2 and T-cytotoxic (Tc)1/Tc2 cells were measured by 
evaluating intracellular IFN-γ and IL-4 levels. The monocyte-
macrophage population was estimated by investigating CD14-
positive/CD16-positive and CD14-positive/CD16-negative 
cells, and regulatory T cells were measured by CD4/CD25 
simultaneous staining. Serum levels of IFN-γ, IL-10 and IL-4 
were also examined.
In addition, bone densitometry (Lunar DPX Pro, Lunar Cor-
poration, Madison, WI 53717, USA) and X-ray of the hands and 
feet were performed at the first visit. The bone densitometry 
measurements were performed at the lumbar spine (L1–L4) 
and proximal femur area.
Therapeutic protocol
Each of the 19 patients was treated with methotrexate (MTX) 
10 mg weekly combined with non-steroidal anti-inflammatory 
drugs (NSAIDs) started at least 3 months before being enrol-
led into the study. If the patient was over 65 years of age or 
had a history of upper gastrointestinal (GI) complications 
(ulcer, bleeding, perforation) or complaints, nimesulide was 
administered 100 mg twice daily. If the patient was below 65 
years of age and was free of GI symptoms, diclofenac 75 mg 
twice daily was given. 
The selection of patients into the alphacalcidol-treated 
group and the control group was made on the basis of having 
osteopenia or not. In 10 patients with osteopenia (<–1 T-score 
by the neck of femur or lumbar spine bone densitometry), oral 
alphacalcidol treatment 0.25 µg twice daily was initiated (this 
group served as the treated arm) and continued throughout 
the whole study period. We chose to treat only the osteopenic 
subgroup because in Hungary alphacalcidol is not a registered 
drug for the treatment of PA, but rather for the treatment of 
osteopenia. The remaining 9 patients with normal bone density 
served as the control arm. 
Topically, all patients used creams with no active ingredients. 
Study end-points
The primary end-points were measurements of the alterations 
in the function of the immune system evaluated by immunolo-
gical laboratory tests and of changes in the clinical parameters 
(VAS, DAS28, PASI scores) in the alphacalcidol-treated and 
control groups. The secondary end-points were the detection 
of the changes in the serum calcium level and in the urine 
calcium/creatinine ratio.
Determination of lymphocyte and monocyte subsets
Immunofluorescent staining for flow cytometric analysis was 
performed by incubating 100 µl of whole blood with the cor-
responding monoclonal antibodies for 30 min. Red blood cells 
were lysed according to the Q-Prep protocol (Beckman-Coulter, 
Fullerton, CA, USA). Samples were subsequently washed in 
phosphate-buffered saline (PBS) containing bovine serum 
albumin (BSA) (1%) and resuspended in 1% paraformalde-
hyde. Lymphocyte and monocyte subsets were identified by 
the three-colour flow cytometry with antibodies to CD3, CD4, 
CD8, CD19, CD56, CD25, CD14 and CD16 (BD Biosciences, 
San Diego, CA, USA, Immunotech, Marseille, France and 
Sigma-Aldrich Co., St Louis, MO, USA). The expression of 
T-lymphocyte activation markers, namely, HLA-DR and CD69 
was also determined on CD3-positive cells with corresponding 
monoclonal antibodies (BD Biosciences). Events were recor-
ded by Coulter EPICS XL flow cytometer (Beckman Coulter 
Inc., Miami, FL, USA). At least 5000 events were counted and 
evaluated for the expression of CD3, CD3/CD4, CD3/CD8, 
CD19, CD3/CD56, CD3/CD69, CD3/HLADR, CD4/CD25bright 
and CD14/CD16.
Evaluation of soluble and intracellular cytokines
Serum levels of IL-10, IL-4 and IFN-γ were measured using 
BD OptEIA ELISA kits (BD Biosciences), according to the 
manufacturer’s instructions. Intracellular flow cytometry 
was utilized to determine the percentage of IFN-γ- and IL-
4-producing lymphocytes within the CD4- and CD8-positive 
subsets. Briefly, heparinized whole blood was diluted 1:1 with 
RPMI medium (Sigma-Aldrich Co.), and cells were stimulated 
for 4 h at 37°C, in 5% CO2 atmosphere with 0.5 mg/ml iono-
mycine (Sigma-Aldrich) and 1 µg/ml phorbol myristate acetate 
(PMA; Sigma-Aldrich) in the presence of 5 mg/ml Brefeldin A 
(Sigma-Aldrich) to induce cytokine production. Lymphocytes 
were then stained with either anti-human CD4-Quantum Red 
or anti-human CD8-Quantum Red (Sigma-Aldrich). Red blood 
cells were subsequently lysed with FACS Lysing Solution (BD 
Biosciences), and lymphocytes were permeabilized with FACS 
Permeabilizing Solution (BD Biosciences). To detect intracel-
lular cytokines, cells were labelled with either anti-human 
IFN-γ-FITC/IL-4-PE (BD Biosciences) or with anti-human 
IL-10 (Caltag Laboratories, Burlingame, CA, USA), washed, 
and fixed with 1% paraformaldehyde. Events were counted by 
Coulter EPICS XL flow cytometer (Beckman Coulter Inc.). 
A gate was set on CD4- or CD8-positive lymphocytes and at 
least 5000 cells were counted and evaluated for the expression 
of IFN-γ and IL-4. 
Statistical analysis
Statistical analysis of the results was performed using an SPSS 
11.0 software. Statistical differences between measured va-
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lues were analysed using a paired t-test. p-values < 0.05 were 
considered statistically significant. All values are shown as 
mean ± standard deviation. 
RESULTS
Clinical data
Nineteen patients with PA were investigated. The mean 
age of the alphacalcidol treated (osteopaenic) group 
was higher (60 ± 8 years) than that of the control group 
(53 ± 13 years). This difference can be explained by 
the increased prevalence of decreased bone density 
with age. Therefore, the older patients had a higher 
probability of having osteopaenia and getting into the 
treated arm. In our opinion this difference in age did 
not influence the immunological status of the groups. 
The disease course of psoriasis in the treated arm was 
shorter (15 ± 11 vs. 21 ± 8 years), while the presence of 
arthritis was almost the same in the two groups (7.7 ± 6 
vs. 8.4 ± 1.4 years).
Before alphacalcidol treatment the clinical and la-
boratory parameters were not significantly different 
between the treated and the control groups. The VAS 
scores were 57 ± 17 vs. 60 ± 21 mm, the DAS scores 
were 45 ± 11 vs. 49 ± 21 mm, and the PASI scores were 
12.8 ± 4.3 vs. 11.9 ± 4.4, respectively, on the average. 
In order to monitor the potential side-effects we looked 
at serum calcium levels and the urine calcium/crea-
tinine ratio. At the start, the serum calcium levels were 
2.34 ± 0.1 mmol/l vs. 2.29 ± 0.06 mmol/l, while the urine 
calcium/creatinine ratios were 0.33 ± 0.19 vs. 0.25 ± 0.29 
in the treated and in control groups, respectively (data 
not shown).
The only significant change in clinical parameters 
was observed in the DAS28. In the alphacalcidol-treated 
group, but not in controls, a continuous decrease in 
DAS28 during the 6 months of follow-up was detected 
reaching 29 ± 10 mm (p = 0.048). The PASI and VAS 
scores also were decreased in the treated group, but 
the difference was not significant. No further signi-
ficant changes in the main clinical parameters were 
detected.
Immunological laboratory parameters
At the start of the study there were no significant dif-
ferences between the two groups with regard to their 
immunological laboratory parameters.
In the treated group a significant decrease in the 
percentage of CD69-positive activated T cells was 
observed (1.54 ± 1.15% vs. 0.56 ± 0.33%, p = 0.04) 
(Fig. 1.). There was also a significant decrease in the 
percentage of IFN-γ-producing CD8-positive T lympho-
cytes (7.6 ± 3.4% vs. 4.3 ± 3.0%, p = 0.04) (Fig. 2.), as 
well as in the serum IFN-γ levels (34.3 ± 25.1 pg/ml vs. 
5.5 ± 4.0 pg/ml, p = 0.03), after 3 months of treatment 
with alphacalcidol (Fig. 3.). These alterations reflect 
a down-regulation in the activation of T cells and a 
decreased cytokine production of cytotoxic T lympho-
cytes in the alphacalcidol-treated group. There were no 
statistically significant changes in the percentages of 
other T-cell populations (CD3/CD4-positive, CD3/CD8-
positive, CD4/IFN-γ-positive, CD4/IL-4-positive, CD8/
IL-4-positive), neither were there significant changes 
in the ratio of regulatory T cells, B cells, NK cells and 
activated monocytes during the first 3 months of follow-
up. However, a non-significant decrease in the ratio of 
CD56-positive NK cells was observed after 6 months 
of alphacalcidol treatment (19.0 ± 6.0% vs. 16.4 ± 6.7% 
ns). In the control group no significant changes in the 
immunological laboratory parameters were observed 
(data not shown).
DISCUSSION
Several animal studies have shown beneficial immuno-
modulatory effects of vitamin D3 and its active meta-
bolites in experimental autoimmune encephalomyelitis 


















Fig. 1. Percentage of CD3/CD69-positive activated T cells. There was a 
significant decrease in the percentage of CD3/CD69-positive T cells in the 
















Fig. 2. Percentage of IFN-γ-producing CD8-positive T cells. A significant 
decrease in the percentage of IFN-γ producing CD8-positive T lymphocytes 
was detected 3 months after introducing the alphacalcidol therapy.
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tion models (23, 24). In experimental arthritis models 
treatment with activated forms of vitamin D3 suppres-
sed the incidence and activity of arthritis (25, 26).
There were only a few human studies on the clinical 
effects of vitamin D3 metabolites in various arthritic 
conditions. Some authors observed a slight, but not 
significant improvement in the clinical and laboratory 
parameters of RA patients after systemic alphacalcidol 
treatment (27, 28)
There is evidence on the clinical effectiveness of oral 
treatment with activated forms of vitamin D3 on skin 
symptoms of psoriatic patients. Perez and co-workers 
(17) applied calcitriol in a 2.4 µg daily dose, with cal-
cium restriction, on patients with plaque-type psoriasis 
with a success rate of 88% without major side-effects. 
In our study a slight but statistically non-significant 
improvement in skin symptoms (e.g. PASI score) was 
observed, though we used much lower doses than the 
other investigators. On the other hand, the clinical 
effects of systemic alphacalcidol treatment on PA 
were examined in only one pilot study. Huckins and 
co-workers (18) conducted a 6-month open-label trial 
in which 10 patients with active PA received 2 µg of 
oral alphacalcidol once daily. They noted statistically 
significant improvements in the tender joint count and 
physician global impression, but immunological labora-
tory data were not recorded (18).
In our present study we found a significant immuno-
modulatory effect during systemic alphacalcidol treat-
ment in patients with polyarticular PA. This effect 
resulted in a continuous decline in the disease activity 
score (DAS28) after 6 months and significant changes 
in different immunological parameters. The percent-
age of CD69-positive activated T cells, the ratio of 
IFN-γ-producing CD8-positive T lymphocytes and the 
serum IFN-γ level were significantly decreased after 3 
months of treatment. Our results clearly indicate that 
the effect of systemic alphacalcidol treatment results 
in a short-term temporary decrease in the activation of 
type 1 immune responses and in a continuous decrease 
in disease activity. Theoretically, the decrease in pain 
arising from the periarticular bone can adulterate the 
results of the DAS28 score. Our belief, however, is that 
the decrease in DAS28 score is really a consequence of 
the immunomodulatory effect of alphacalcidol. For once 
the articular pain is not a part of the clinical picture of 
osteopaenia, since the osteopaenia is a basically a silent 
disease. Beside this, the components of DAS28 (joint 
swelling and tenderness, erythrocyte sedimentation 
rate) are quite reliable markers of the arthritis activity. 
Finally, the follow-up period (6 months) is too short 
for a substantial increase in bone density following 
alphacalcidol treatment. The temporary decrease in the 
parameters at 3 months was associated with a decrease 
in clinical disease activity at 6 months, although there 
was no clear causative relationship between these data. 
Yet, we believe that these findings point towards the 
fact that the administration of this drug has a beneficial 
immunological effect in these patients.
There is evidence that psoriasis and PA are T-cell 
driven type 1 immune-mediated diseases. CD8-positive 
T lymphocytes play a crucial role in the pathogenesis of 
PA. In the synovial fluid and in the synovium there is a 
dominant CD8-positive T-cell population and these cells 
may be the driving force behind the immune response 
in the PA joint (29). Cytokines secreted from immuno-
competent cells induce proliferation and activation of 
the synovial and epidermal fibroblasts leading to clinical 
manifestations of arthritis in patients. Moreover, serum 
levels of different cytokines can be a marker of disease 
activity in patients with PA (30).
IFN-γ plays an important role in the pathogenesis 
of PA. It increases the expression of MHC-II antigens 
and intercellular adhesion molecule-1 (ICAM-1) on the 
surfaces of synovial membranes and keratinocytes, and 
facilitates the production of pro-inflammatory cytokines 
(TNF-α, IL-1, IL-2, IL-6, IL-8) (31). IFN-γ also shifts 
the immune response towards a type 1 direction, and 
decreases suppressor T-cell activity (32, 33). 
Our results support the idea that the observed decline 
in disease activity can be explained by the alphacal-
cidol-mediated decrease in type 1 immune response. 
We believe that the administration of alphacalcidol to 
patients with PA improves the laboratory parameters and 
the clinical disease course and will become a valuable 
alternative in the future.
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